This company has been acquired
PRTK Aperçu des actions
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use.
| Score flocon de neige | |
|---|---|
| Évaluation | 5/6 |
| Croissance future | 4/6 |
| Performances passées | 0/6 |
| Santé financière | 1/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
Paratek Pharmaceuticals, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$2.23 |
| Plus haut sur 52 semaines | US$3.65 |
| Plus bas sur 52 semaines | US$1.29 |
| Bêta | 1.7 |
| 1Variation sur 1 mois | 2.29% |
| Variation sur 3 mois | 0.91% |
| Variation sur 1 an | -2.62% |
| 3Variation sur 3 ans | -60.95% |
| Variation sur 5 ans | -77.01% |
| Évolution depuis l'introduction en bourse | -86.06% |
Nouvelles et mises à jour récentes
Recent updates
Improved Revenues Required Before Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock's 77% Jump Looks Justified
Apr 17
Paratek Pharmaceuticals: Patience Is Wearing Thin
Aug 24Paratek Pharmaceuticals GAAP EPS of -$0.33 beats by $0.01, revenue of $29.6M beats by $0.42M
Aug 03Paratek Pharmaceuticals: A Deeply Undervalued Antibiotic Company
Jan 03The Play On Paratek Pharmaceuticals
Oct 18Peeking Back In On Paratek Pharmaceuticals
Aug 07Paratek Pharma launches Phase 2b Nuzyra study in nontuberculous mycobacterial
Jun 16Paratek shares rise after FDA approves NUZYRA oral only dosing regimen
Jun 01Paratek Offers Long-Term Value Potential In The Difficult Antibiotic Business
Apr 27Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK): Are Analysts Optimistic?
Mar 01Could The Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ownership Structure Tell Us Something Useful?
Feb 01Paratek Pharmaceuticals secures $60M non-recourse loan for Hercules debt repayment
Jan 04Paratek Pharmaceuticals: 100%+ Upside As Nuzyra Sales Scale
Dec 01Paratek Pharmaceuticals, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 06Rendement pour les actionnaires
| PRTK | US Pharmaceuticals | US Marché | |
|---|---|---|---|
| 7D | 2.3% | 0.3% | 0.3% |
| 1Y | -2.6% | 23.6% | 38.3% |
Rendement vs Industrie: PRTK underperformed the US Pharmaceuticals industry which returned 15.1% over the past year.
Rendement vs marché: PRTK underperformed the US Market which returned 13.8% over the past year.
Volatilité des prix
| PRTK volatility | |
|---|---|
| PRTK Average Weekly Movement | 1.6% |
| Pharmaceuticals Industry Average Movement | 9.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.0% |
Cours de l'action stable: PRTK has not had significant price volatility in the past 3 months.
Volatilité au fil du temps: PRTK's weekly volatility has decreased from 13% to 2% over the past year.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1996 | 269 | Evan Loh | www.paratekpharma.com |
Paratek Pharmaceuticals, Inc. Résumé des fondamentaux
| PRTK statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$127.83m |
| Bénéfices(TTM) | -US$62.73m |
| Recettes(TTM) | US$177.00m |
0.7x
Ratio P/S-2.0x
Ratio P/ELe site PRTK est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| PRTK compte de résultat (TTM) | |
|---|---|
| Recettes | US$177.00m |
| Coût des recettes | US$64.13m |
| Marge brute | US$112.87m |
| Autres dépenses | US$175.60m |
| Les revenus | -US$62.73m |
Derniers bénéfices déclarés
Jun 30, 2023
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -1.09 |
| Marge brute | 63.77% |
| Marge bénéficiaire nette | -35.44% |
| Ratio dettes/capitaux propres | -128.3% |
Quelles ont été les performances à long terme de PRTK?
Voir les performances historiques et les comparaisons